Tenofovir Prophylaxis During Pregnancy for the Elimination of Mother-To-Child Transmission of Hepatitis B Virus in Pilot Provinces, Thailand: A Cost-Effectiveness Analysis

Janekrongtham, Chawisar; Punsuwan, Niramon; Thitichai, Phanthanee; Lertpiriyasuwat, Cheewanan; Pan-ngum, Wirichada; Poovorawan, Kittiyod; Jantarapakde, Jureeporn; Tangkijvanich, Pisit

doi:10.2139/ssrn.4153439

Cited by 1 publication

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The WHO recommends the use of TDF during pregnancy to prevent mother-to-child HBV transmission, and the first dose of HBV vaccine should be given as soon as possible after birth, preferably within 24 hours [61]. Although most trials demonstrating the efficacy of antiviral therapy in preventing mother-to-child transmission included the administration of HBV immune globulin to all infants [61], recent real-world analysis from Thailand showed that immune globulin may not be necessary and cost effective in the antiviral era [62].…”

Section: Prevention Of Mother-to-child Hbv Transmissionmentioning

confidence: 99%

Current practice and recommendations for management of hepatitis B virus in people living with HIV in Asia

Lui,

Wong,

Yang

et al. 2023

HIV Medicine

View full text Add to dashboard Cite

BackgroundThe prevalence of HIV and hepatitis B virus (HBV) co‐infection is higher in Asia than in Europe and North America and varies significantly between different regions within Asia. Important routes of transmission of both these infections include high‐risk unprotected sexual contact, intravenous drug use, and transmission of maternal infection perinatally or in early childhood. While life expectancy among people living with HIV has been extended with effective antiretroviral therapy (ART), HBV‐induced liver injury and complications have emerged as a leading cause of morbidity and mortality in people living with HIV.ObjectivesThis article describes the prevalence of co‐infection, current clinical practice, and recommendations for the management of people living with HIV‐HBV co‐infection in Asia.Results and ConclusionsScreening for HBV should occur at the time of HIV diagnosis; however, HBV screening rates in people living with HIV in Asia vary widely by region. Similarly, people with HBV should be screened for HIV before initiation of HBV antiviral therapy. People with HIV‐HBV co‐infection should be assessed for liver damage and risk factors for liver disease and be monitored regularly for liver complications and HBV DNA. Medical treatment with ART is lifelong and includes tenofovir and lamivudine or emtricitabine, unless intolerant or contraindicated, as these are active against both HIV and HBV. HBV vaccination programmes are effective in reducing co‐infection rates. Mother‐to‐child transmission can be prevented through measures such as vaccination, antenatal screening, and treatment of pregnant women who are infected.

show abstract

Section: Prevention Of Mother-to-child Hbv Transmissionmentioning

confidence: 99%